KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oscar Health (OSCR) Receivables - Net (2020 - 2025)

Historic Receivables - Net for Oscar Health (OSCR) over the last 6 years, with Q4 2025 value amounting to $442.6 million.

  • Oscar Health's Receivables - Net rose 4012.59% to $442.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $442.6 million, marking a year-over-year increase of 4012.59%. This contributed to the annual value of $442.6 million for FY2025, which is 4012.59% up from last year.
  • As of Q4 2025, Oscar Health's Receivables - Net stood at $442.6 million, which was up 4012.59% from $445.5 million recorded in Q3 2025.
  • Oscar Health's Receivables - Net's 5-year high stood at $488.8 million during Q1 2025, with a 5-year trough of $75.9 million in Q1 2021.
  • In the last 5 years, Oscar Health's Receivables - Net had a median value of $211.3 million in 2022 and averaged $258.4 million.
  • As far as peak fluctuations go, Oscar Health's Receivables - Net skyrocketed by 11189.49% in 2021, and later crashed by 702.44% in 2023.
  • Oscar Health's Receivables - Net (Quarter) stood at $138.4 million in 2021, then soared by 56.4% to $216.5 million in 2022, then dropped by 7.02% to $201.3 million in 2023, then surged by 56.95% to $315.9 million in 2024, then soared by 40.13% to $442.6 million in 2025.
  • Its Receivables - Net stands at $442.6 million for Q4 2025, versus $445.5 million for Q3 2025 and $465.4 million for Q2 2025.